Axsome Biotherapeutics Stock Surges As FDA Grants Priority Review

Axsome Biotherapeutics announced that the US regulator has granted Priority Review to its investigational therapy for agitation associated with Alzheimer...

January 05, 2026 | Monday | News
Enveric Biosciences Closes $3.1 Million Warrant Exercise Financing

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuropla...

December 15, 2025 | Monday | News
Bavarian Nordic Announces Intention to Launch DKK 500 Million Share Buy-Back Program

Bavarian Nordic A/S  announced its intent to launch a one-time share buy-back program of up to DKK 500 million to be executed over the next 12 month...

December 03, 2025 | Wednesday | News
Merck Alerts Investors to Tutanota’s Unsolicited Mini-Tender Offer Priced Significantly Below Market

-Merck (NYSE: MRK), known as MSD outside the United States and Canada, has been notified that Tutanota LLC (Tutanota) has commenced an unsolicited &ldquo...

November 24, 2025 | Monday | News
Minerva Neurosciences Secures up to $200 Million to Advance Roluperidone Through Confirmatory Phase 3 Trial and NDA Resubmission

Minerva secures $80 million up front and up to an additional $80 million subject to the full exercise of Tranche A warrants. Minerva and the FDA have ...

October 22, 2025 | Wednesday | News
Rani Therapeutics Enters $1 Billion Collaboration with Chugai for Oral Biologics Development

Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $10...

October 20, 2025 | Monday | News
Propanc Biopharma Enters Strategic $100M Financing Agreement with Hexstone Capital

Propanc Biopharma, Inc. ("Propanc" or the "Company") is pleased to announce it has entered into a strategic financing agreement of up to $100 million wit...

October 16, 2025 | Thursday | News
The 2025 Biopharma Index: Stocks Set to Outperform in a Post-AI Market

The biopharmaceutical industry enters 2025 on strong footing, bolstered by scientific breakthroughs and a wave of digital innovation. In the post-AI market...

October 10, 2025 | Friday | Analysis
Zenas BioPharma Secures Global Rights to Orelabrutinib, Expands Pipeline with Novel IL-17AA/AF and TYK2 Inhibitors

Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO) and InnoCare Pharma Limited (&ldqu...

October 09, 2025 | Thursday | News
Barinthus Bio and Clywedog Therapeutics Announce Definitive Merger Agreement to Create Nasdaq-Listed Clywedog Therapeutics, Inc.

The combined company, Clywedog Therapeutics, will bring a portfolio that includes three differentiated, clinical stage product candidates which are bei...

October 01, 2025 | Wednesday | News
Inmagene and Ikena Complete $75M Merger to Launch ImageneBio, Inc. on Nasdaq as “IMA”

The combined company will operate under the name “ImageneBio, Inc.” and will begin trading on Nasdaq under the ticker symbol “IMA&rdquo...

July 28, 2025 | Monday | News
23andMe Board Rejects CEO Anne Wojcicki’s Lowball Buyout Offer, Raising Big Questions for Investors

The Special Committee of the Board of Directors of 23andMe Holding Co. (“23andMe” or the “Company”) (Nasdaq: ME) today confirmed ...

March 04, 2025 | Tuesday | Analysis
LSPedia Secures MMCAP Infuse DSCSA Compliance Contract to Expand U.S. Reach

LSPedia, a global leader in pharmaceutical traceability and supply chain SaaS solutions, has secured its second major U.S. government contract, the MMCAP I...

February 27, 2025 | Thursday | News
Biogen and Stoke Therapeutics Collaborate on Zorevunersen for Dravet Syndrome Treatment

Biogen Inc.  and Stoke Therapeutics, Inc. announced a collaboration for the development and commercialization of zorevunersen, a potential f...

February 19, 2025 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close